Management of fibromyalgia: Current pharmacologic therapies & recommendations for therapeutic optimisation
|
|
- Kristian Jenkins
- 5 years ago
- Views:
Transcription
1 Page 1 of 5 Management Management of fibromyalgia: Current pharmacologic therapies & recommendations for therapeutic optimisation M Slim, EP Calandre* Abstract Introduction Fibromyalgia is a chronic musculoskeletal pain disorder characterised by complex underlying pathophysiological mechanisms, a complexity that requires careful adjustment of treatment tailored to patient s needs. This article reviews the various pharmacologic options currently used or are under investigation for the treatment of fibromyalgia. Discussion Drugs currently used in clinical practice for the treatment of fibromyalgia possess varying degrees of evidence for efficacy. Antidepressants and calcium alfa2delta blockers (mainly pregabalin) are the agents with the highest level of evidence in fibromyalgia. Drugs whose evidence of efficacy that is less pronounced include sodium oxybate, 5-HT3 antagonists (tropisetron and dolasetron), and pramipexole. On the other hand, analgesics (excluding the combination of tramadol and paracetamol), antipsychotics and sedative-hypnotics had less or no benefit in fibromyalgia. The combination of two or more drugs with different mechanisms of action and non-overlapping side-effects profile can be necessary in the most severely affected patients. Conclusion As the benefits of the pharmacologic agents for the treatment of fibromyalgia are limited, a multidisciplinary treatment plan that includes a combination of pharmacologic and non-pharmacologic therapies is recommended in the management of *Corresponding author calandre@gmail.com Instituto de Neurociencias, Universidad de Granada, Spain the disease. Adequate communication techniques should be adopted to potentiate placebo and minimize nocebo effects in clinical practice. Introduction Fibromyalgia syndrome is a musculoskeletal pain disorder characterised by chronic generalised pain and several other somatic and psychological symptoms, such as fatigue, stiffness, sleep disturbances, depression, anxiety, and cognitive dysfunction 1. It is a prevalent syndrome affecting 2% to 5% of the general population, with higher prevalence among females 2 although the exact female/male ratio has been recently questioned 3. The prevalence rates are influenced by the diagnostic criteria of fibromyalgia, which were first formulated in 1990 by the American College of Rheumatology 4 (ACR), requiring the presence of tenderness in at least 11 out of 18 musculoskeletal tender points lasting a minimum of 3 months. These criteria were modified by the ACR in 2010 to assess pain with the Widespread Pain Index (WPI) without the requirement to explore tender points, and add a Symptom Severity (SS) Scale that evaluates the intensity of fatigue, sleep problems, and cognitive dysfunction, and also takes into consideration the presence of other somatic symptoms 5. Fibromyalgia is classified as a central sensitization syndrome, which is associated with abnormal pain processing manifested in the presence of hyperalgesia, allodynia and referred pain 6. However, the exact pathophysiological mechanisms underlying the disease are not fully understood yet, despite the recognition of several genetic and environmental factors involved in fibromyalgia development. The complex clinical presentation of patients with fibromyalgia and the unclear pathophysiological mechanisms underlying the disease complicate the attempts toward formulating a clear treatment plan in the management of this syndrome. However, several treatment guideline recommendations for the management of fibromyalgia are currently available and a consensus exists about the competence of a multimodal approach in the treatment of fibromyalgia, through the combination of both pharmacologic and non-pharmacologic therapies 7. This article reviews the different pharmacological treatment options available for the management of fibromyalgia syndrome. Discussion The authors have referenced some of their own studies in this review. These referenced studies have been conducted in accordance with the Declaration of Helsinki (1964) and the protocols of these studies have been approved by the relevant ethics committees related to the institution in which they were performed. All human subjects, in these referenced studies, gave informed consent to participate in the studies. The use of medications on offlabel basis for the management of fibromyalgia is frequent due to the limited number of drugs approved by the drug regulatory authorities. Only three drugs have been authorised by the U.S. Food and Drug Administration (FDA) for their use in fibromyalgia: pregabalin, duloxetine, and milnacipran and none by the European Medicines Agency (EMA). A focus on the major classes of drugs currently used in the management of fibromyalgia is discussed below.
2 Page 2 of 5 Antidepressants Antidepressants have been shown to be effective in the treatment of different chronic pain conditions such as neuropathic pain, headaches, cancer pain, lower back pain, or irritable bowel syndrome in addition to fibromyalgia 8. Antidepressants of various classes such as tricyclic antidepressants (TCAs), serotonin and norepinephrine reuptake inhibitors (SNRIs), and selective serotonin reuptake inhibitors (SSRIs) have been extensively studied in the treatment of fibromyalgia. TCAs, the oldest class of antidepressants used in the treatment of fibromyalgia, have been shown to be effective in fibromyalgia treatment used at low doses (<75 mg/day) 8. In a meta-analysis, they were associated with significant improvement in pain, sleep disturbances, fatigue and health-related quality of life in patients with fibromyalgia, and their effect sizes in improving pain and sleep were larger compared with other classes of antidepressants 9. The superiority of the TCA amitriptyline was also evident in another meta-analysis that compared it with duloxetine and milnacipran; however, the methodological limitations of amitriptyline studies prevented the authors from acknowledging it as the gold standard in the treatment of fibromyalgia 10. Cyclobenzaprine, a centrally acting muscle relaxant structurally related to TCAs, has also demonstrated effectiveness in reducing pain and improving sleep in patients with fibromyalgia 11. SNRIs are characterised by their selective inhibition of serotonin and norepinephrine reuptake, a characteristic that confers them better tolerability and side-effects profile as compared with the non-selective TCAs. Duloxetine and milnacipran are the SNRIs most frequently used in the treatment of fibromyalgia. Although venlafaxine was the first SNRI studied in fibromyalgia, it is not usually used in clinical practice for the management of this condition given that only two uncontrolled studies investigating its use in fibromyalgia have been published in contrast with the large amount of evidence available for duloxetine and milnacipran. Duloxetine ( mg/day) and milnacipran ( mg/day) have been linked to beneficial outcomes in the treatment of fibromyalgia, improving pain, sleep, fatigue, depression, and health-related quality of life 9. In another meta-analysis that studied the effects of each SNRI separately, duloxetine and milnacipran were shown to significantly reduce pain, depressive symptoms and improved quality of life; however, only duloxetine resulted in significant improvements in sleep disturbances, and fatigue was significantly reduced by milnacipran exclusively 10. Data concerning the effectiveness of SSRIs in the treatment of fibromyalgia confirm previous findings of their limited role in the treatment of other chronic pain conditions 8. They have been shown to improve pain, sleep, fatigue, depression, and quality of life, although with small and nonsubstantial effect sizes 9. Their limited side-effects profile consequent to their selectivity to serotonin receptors designates them as an alternative in case of non-tolerability to other antidepressants. Trazodone, an old second generation antidepressant, is characterised by a sedative hypnotic activity at low doses. It has been shown, in two uncontrolled studies, to improve sleep quality, anxiety, and depression but to lack efficacy in relieving pain 12,13. Anti-epileptics Anti-epileptics are widely used in the treatment of chronic pain, namely neuropathic pain conditions such as post-herpetic neuralgia, diabetic peripheral neuropathy, and trigeminal neuralgia 14. Evidence of efficacy in the treatment of fibromyalgia is exclusively limited to the calcium channel modulators class of anti-epileptics, pregabalin, and gabapentin. Their effect in pain modulation is mediated through the inhibition of α2δ voltage-gated calcium channel, leading to a blockade in the release of excitatory neuro transmitters involved in the process of pain perception 15. In a meta-analysis studying the effect of gabapentin and pregabalin in fibromyalgia, a strong evidence for their efficacy in improving pain, sleep disturbances and health-related quality of life was found, but with small effect sizes; on the other hand, they were associated with a non-substantial effect on fatigue and anxiety, and lacked effect on depression 16. Pregabalin was the first drug to be approved by the FDA in the treatment of fibromyalgia in Pregabalin s stronger evidence for efficacy in fibromyalgia and its surpassing pharmacokinetic and pharmacodynamic profiles designate it as the more desirable antiepileptic agent in fibromyalgia as compared with gabapentin except in cases of non-tolerability, a condition that advocates gabapentin use 17. Analgesics Non-steroidal Anti-inflammatory Drugs Although NSAIDs are widely used among patients with fibromyalgia, limited evidence exists about their efficacy in this condition. This can be explained by the non-inflammatory nature of the disease that eliminates a direct potential benefit of these compounds on the pathogenesis of fibromyalgia. Subsequently, NSAIDs are not widely examined in fibromyalgia and investigations concerning their use in fibromyalgia were limited to a small number of controlled clinical trials that have demonstrated little or no efficacy 18 in the long-term treatment of the disease. Opioids Opioids are widely used in the treatment of fibromyalgia despite the lack of evidence for efficacy. On the contrary, a general impression that they are not effective in fibromyalgia exists in clinical practice. On that
3 Page 3 of 5 basis, besides their side effect profile and concerns about potential abuse, it is advised to avoid opioids use in fibromyalgia 19. Interestingly, opioid antagonists have produced beneficial effects when used in fibromyalgia, where low-dose naltrexone, a competitive opioid receptor antagonist has been associated with significant reduction of pain, improved general satisfaction with life and improved mood, however, neither fatigue nor sleep were improved 19. Other Analgesics Tramadol and tapentadol are two structurally related centrally acting analgesics that combine an agonistic action on μ opioid receptors with monoamines uptake inhibition. Compared with tramadol, tapentadol has higher affinity toward μ opioid receptors and a selective inhibition of noradrenaline reuptake with minimal effect on serotonin reuptake 20. In a double-blind placebo controlled trial, the combination of tramadol-acetaminophen led to a significant reduction in pain among patients with fibromyalgia, in addition to a significant improvement in the fibromyalgia impact questionnaire 21. However, it remains preferable to avoid the chronic use of tramadol sparing it to the periods of flareups. On the other hand, tapentadol has not been studied in fibromyalgia yet; however, its efficacy results in the management of other chronic pain conditions are encouraging 22 and point toward a potential promising role in fibromyalgia treatment. Antipsychotics Considering their analgesic effect and their role in improving sleep problems, a postulation of a possible role for antipsychotics in fibromyalgia has been suggested. However, most of the studies investigating the role of first or second generation antipsychotics such as olanzapine, quetiapine, amisulpride, and levomepromazine in fibromyalgia have been uncontrolled. To date, only quetiapine has been evaluated in randomised controlled trials and only preliminary results have been published; additional information is needed before concluding if this drug can be considered as a useful therapeutic alternative for the treatment of fibromyalgia 23. Other Drugs Sodium Oxybate Sodium oxybate, the sodium salt of gamma-hydroxybutyrate, is an endogenous metabolite of the inhibitory neurotransmitter gammaaminobutyric acid. It gained an FDA orphan drug status for the treatment of cataplexy and daytime sleepiness in patients suffering from narcolepsy. The use of sodium oxybate in fibromyalgia has been investigated in four randomised clinical trials. It has improved scores of the different pain scales, fatigue, sleep disturbances, fibromyalgia impact questionnaire and the patient global impression of change. However, and due to the concerns of potential abuse, it failed to gain the FDA approval in the treatment of fibromyalgia 24. Sedative-hypnotics Clinical trials conducted to investigate the role of sedative hypnotics in fibromyalgia point toward a limited role of these agents in the treatment of fibromyalgia. Benzodiazepines such as alprazolam, bromazepam, and temazepam as well as two non-benzodiazepines GABA-A agonistszolpidem and zopiclone only improved sleep without significant improvement of other symptoms such as pain or fatigue 25. Dopamine Agonists In view of the analgesic effects of dopamine, a suggestion of beneficial outcomes that could be attained from the use of dopamine agonists in fibromyalgia was considered. However, only pramipexole has induced, in a randomised clinical trial, improvements in pain, fatigue and global well-being, whereas, neither ropinirole nor the novel extended-release formulation of ropinirole were capable of significantly reducing pain among patients with fibromyalgia compared to placebo HT3 Antagonists Considering the analgesic effects of 5-HT3 antagonists, several clinical trials investigated the role of tropisetron orally and intravenously for the treatment of fibromyalgia, where both routes of administration have been linked to a significant reduction of pain 27. Similarly, intravenous dolasetron significantly reduced pain in a 12-month randomised clinical trial in patients with fibromyalgia. These agents have been recommended primarily to patients presenting with substantial pain levels but lacking psychological distress 27. Designing the Treatment Plan in Fibromyalgia: Mono or Polytherapy? The broad range of symptomatology spectrum in fibromyalgia complicates the attempts of finding a gold standard agent capable of alleviating the various symptoms of this syndrome. As commented above, the efficacy of pharmacologic agents in fibromyalgia is limited. In a meta-analysis that compared the three drugs approved by the FDA in fibromyalgia (pregabalin, duloxetine, and milnacipran), only small effect sizes (<0.40) were obtained in alleviating the various symptoms assessed (pain, fatigue, sleep, depressed mood, and healthrelated quality of life) with each of the three drugs considered 28. These facts easily explain that, in clinical practice, polytherapy is seen in a considerable proportion of patients with fibromyalgia, although a very limited number of clinical trials have investigated the efficacy and safety of drug combinations in fibromyalgia. This constitutes a challenging issue for healthcare professionals, who need to take their decisions about drug combinations
4 Page 4 of 5 based on solid pharmacological knowledge of each agent, so that efficacy is maximized and overlapping side effects are minimized 29. Placebo and Nocebo effects: Potential In luence in Fibromyalgia Placebo effect is defined as the beneficial outcome(s) experienced by a patient following a nonspecific treatment, while nocebo refers to the negative outcome(s) experienced and they are both caused by cognitive factors relating to the patient s perception of the particular intervention rather than the intervention itself. In fibromyalgia, substantial magnitudes of placebo and nocebo responses were seen in a meta-analysis of 18 trials of drugs applying for approval for fibromyalgia (duloxetine, milnacipran, pregabalin, and sodium oxybate), with a pooled estimate of 50% pain reduction by placebo reaching 18.6% (95% CI 17.4% to 19.9%) and a pooled estimate of drop out due to adverse events in placebo reaching 10.9% (95% CI 9.9% to 11.9%) 30. In another meta-analysis, 67.2% (95% CI 51% to 81.5%) of 2,026 placebo treated patients with fibromyalgia reported at least one adverse event, and 9.5% (95% CI 8.3% to 10.9%) discontinued placebo treatment because of intolerance, where nocebo dropouts in fibromyalgia were fourfold and twofold higher than those seen in multiple sclerosis treatment and migraine preventive treatment, respectively 31. Consequently, a considerable bias to the results of trials in fibromyalgia could be attributed to placebo and nocebo effects, which suggests the need for optimizing clinical trial designs and employing adequate methodology to minimize the confounding impact of such effects. In contrast to clinical investigators, placebo effect constitutes a potential add-on therapeutic tool for clinicians who try to maximize it through warm and empathic interactions with patients. On the other hand, nocebo effects are undesirable for both clinicians and clinical investigators who aim to reduce them through authorised patient concealment of side effects, educating patients about the possibility of nocebo responses, in addition to reassuring, empathetic and supportive communication 30. Conclusion Fibromyalgia is a complex musculoskeletal syndrome whose clinical management represents a challenging and difficult task for healthcare professionals. Pharmacologic therapy should be tailored based on the individual patients symptoms using one or several drugs simultaneously. However, drugs alone only induce a limited benefit in fibromyalgia. A multidisciplinary treatment plan, including a combination of pharmacologic and non-pharmacologic therapies has shown to be effective and therefore should be adopted. The relevance of placebo and nocebo effects in fibromyalgia requires the use of adequate communication techniques to potentiate placebo and minimize nocebo effects in clinical practice. References 1. Smith HS, Harris R, Clauw D. Fibromyalgia: an afferent processing disorder leading to a complex pain generalized syndrome. Pain Physician Mar-Apr;14(2):E Queiroz LP. Worldwide epidemiology of fibromyalgia. Curr Pain Headache Rep Aug;17(8): Wolfe F, Brähler E, Hinz A, Häuser W. Fibromyalgia prevalence, somatic symptom reporting, and the dimensionality of polysymptomatic distress: results from a survey of the general population. Arthritis Care Res (Hoboken) May;65(5): Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia: report of the multicenter criteria committee. Arthritis Rheum Feb;33(2): Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Katz RS, Mease P, et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res May;62(5): Yunus MB. Fibromyalgia and overlapping disorders: the unifying concept of central sensitivity syndromes. Semin Arthritis Rheum Jun;36(6): Häuser W, Thieme J, Turk DC. Guidelines on the management of fibromyalgia syndrome a systematic review. Eur J Pain Jan;41(1): Verdu B, Decosterd I, Buclin T, Stiefel F, Berney A. Antidepressants for the treatment of chronic pain. Drugs. 2008;68(18): Häuser W, Wolfe F, Tölle T, Üçeyler N, Sommer C. The role of antidepressants in the management of fibromyalgia syndrome: a systematic review and meta-analysis. CNS Drugs Apr 1;26(4): Häuser W, Petzke F, Üçeyler N, Sommer C. Comparative efficacy and acceptability of amitriptyline, duloxetine and milnacipran in fibromyalgia syndrome: a systematic review with metaanalysis. Rheumatology (Oxford) Mar;50(3): Tofferi JK, Jackson JL, O Malley PG. Treatment of fibromyalgia with cyclobenzaprine: a meta-analysis. Arthritis Rheum Feb;51(1): Morillas-Arques P, Rodriguez- Lopez CM, Molina-BareaRocio, Rico- Villademoros F, Calandre EP. Trazodone for the treatment of fibromyalgia: an openlabel, 12-week study. BMC Musculoskelet Disord Sep;11: Calandre EP, Morillas-Arques P, Molina-Barea R, Rodriguez-Lopez CM, Rico-Villademoros F. Trazodone plus pregabalin combination in the treatment of fibromyalgia: a two-phase, 24-week, open-label uncontrolled study. BMC Musculoskelet Disord May;12: Sullivan MD, Robinson JP. Antidepressant and anticonvulsant medication for chronic pain. Phys Med Rehabil Clin N Am May;17(2): Sills GJ. The mechanisms of action of gabapentin and pregabalin. Curr Opin Pharmacol Feb;6(1): Häuser W, Bernardy K, Üçeyler N, Sommer C. Treatment of fibromyalgia syndrome with gabapentin and pregabalin: a meta-analysis of randomized controlled trials. Pain Sep;145(1-2): Bockbrader HN, Wesche D, Miller R, Chapel S, Janiczek N, Burger P. A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin. Clin Pharmacokinet Oct;49(10):661 9.
5 Page 5 of Lautenschlager J. Present state of medication therapy in fibromyalgia syndrome. Scand J Rheumatol Suppl. 2000;113: Ngian GS, Guymer EK, Littlejohn GO. The use of opioids in fibromyalgia. Int J Rheum Dis Feb;14(1): Raffa RB, Buschmann H, Christoph T, Eichenbaum G, Englberger W, Flores CM, et al. Mechanistic and functional differentiation of tapentadol and tramadol. Expert Opin Pharmacother Jul;13(10): Bennett RM, Kamin M, Karim R, Rosenthal N. Tramadol and acetaminophen combination tablets in the treatment of fibromyalgia pain: a double-blind, randomized, placeb-controlled study. Am J Med May;114(7): Riemsma R, Forbes C, Harker J, Worthy G, Misso K, Schäfer M, et al. Systematic review of tapentadol in chronic severe pain. Curr Med Res Opin Oct;27(10): Calandre EP, Rico-Villademoros F. The role of antipsychotics in the management of fibromyalgia. CNS Drugs Feb;26(2): Swick TJ. Sodium oxybate: a potential new pharmacological option for the treatment of fibromyalgia syndrome. Ther Adv Musculoskelet Dis Aug;3(4): Lawson K. Treatment options and patient perspectives in the management of fibromyalgia: future trends. Neuropsychiatr Dis Treat Dec;4(6): Wood PB, Holman AJ. An elephant among us: the role of dopamine in the pathophysiology of fibromyalgia. J Rheumatol Feb;36(2): Seidel MF, Müller W. Differential pharmacotherapy for subgroups of fibromyalgia patients with specific consideration of 5-HT3 receptor antagonists. Expert Opin Pharmacother Jun;12(9): Häuser W, Petzke F, Sommer C. Comparative efficacy and harms of duloxetine, milnacipran and pregabalin in fibromyalgia syndrome. J Pain Jun;11(6): Calandre EP, Rico-Villademoros F, Rodríguez-López CM. Monotherapy or combination therapy for fibromyalgia treatment? Curr Rheumatol Rep Dec;14(6): Häuser W, Sarzi-Puttini P, Tölle TR, Wolfe F. Placebo and nocebo responses in randomised controlled trials of drugs applying for approval for fibromyalgia syndrome treatment: systematic review and meta-analysis. Clin Exp Rheumatol Nov-Dec;30(6 Suppl 74): Mitsikostas DD, Chalarakis NG, Mantonakis LI, Delicha EM, Sfikakis PP. Nocebo in fibromyalgia: meta-analysis of placebo-controlled clinical trials and implications for practice. Eur J Neurol May;19(5):
The Role of Pregabalin in Fibromyalgia
The Role of Pregabalin in Fibromyalgia Sofia Exarchou Resident at Internal Medicine and Rheumatology at the University Hospital of Skåne, Malmö-Lund Metsovo Greece 2011 History Gowers 1904 Hench 1976 Smythe
More informationNational Horizon Scanning Centre. Pregabalin (Lyrica) for fibromyalgia. September 2007
Pregabalin (Lyrica) for fibromyalgia September 2007 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a definitive
More informationIf Not Opioids then LEAH EDMONDS CSHP OCTOBER 26, 2017
If Not Opioids then what LEAH EDMONDS CSHP OCTOBER 26, 2017 Disclosure Nothing to disclose Objectives Identify various non-opioid options for the treatment of chronic non cancer pain Choose appropriate
More informationFibromyalgia Update. Presenter: Manfred Harth MD FRCPC
Fibromyalgia Update Presenter: Manfred Harth MD FRCPC Fibromyalgia Update Manfred Harth MD FRCPC Disclosures Member Pfizer Canada Medical Advisory Committee on Lyrica (till April 2013) Abbvie : Payment
More informationHeadaches, 37, 42 Hypnotherapy, 101t, 106 Hypothalamic-pituitary-adrenal (HPA) axis, 59, 61, 63, 64, 65
INDEX Note: page numbers in italic typeface indicate figures. Page numbers followed by a t indicate tables. Abbreviations are for terms listed on pages 135-137. Acetaminophen/tramadol in fibromyalgia,
More information10/19/12. Moving from Mechanisms to Treatment in Chronic Pain Patients. Daniel Clauw, MD Disclosures
10/19/12 Moving from Mechanisms to Treatment in Chronic Pain Patients Daniel Clauw, MD University of Michigan Ann Arbor, MI Daniel Clauw, MD Disclosures Research/Grants: Forest Laboratories, Inc.; Nuvo
More informationIF I M NOT TREATING WITH OPIOIDS, THEN WHAT AM I SUPPOSED TO USE?
NON-OPIOID TREATMENT OPTIONS FOR CHRONIC PAIN Alison Knutson, PharmD, BCACP Medication Management Pharmacist Park Nicollet Creekside Clinic Dr. Knutson indicated no potential conflict of interest to this
More informationIndex. Note: Page numbers of article titles are in boldface type.
Note: Page numbers of article titles are in boldface type. A Abuse, child, 255 Activities of daily living, energy conservation in, 385 Acupuncture, 400 401 Adrenergic receptors, in pain generation, 286
More informationFran Pulver, MD - PM&R Laurie Bell, PT - Physical Therapy Gregg Weidner, MD - Anesthesia Steven Severyn, MD, MBA, MSS - Anesthesia
Fran Pulver, MD - PM&R Laurie Bell, PT - Physical Therapy Gregg Weidner, MD - Anesthesia Steven Severyn, MD, MBA, MSS - Anesthesia Case Presentation-Fibromyalgia 30 year old female Chief complaint of back
More informationFibromyalgia: What Primary Care Providers Need to Know
Learning Objectives Fibromyalgia: What Primary Care Providers Need to Know Susan Hutchinson, MD Director, Orange County Migraine & Headache Center Volunteer Clinical Faculty, UC Irvine Department of Family
More informationFibromyalgia. November 3, 2018 Raymond Hong, MD, MBA
Fibromyalgia November 3, 2018 Raymond Hong, MD, MBA The following report is proprietary information and constitutes trade secrets of The MetroHealth System and may not be disclosed in whole or part to
More information10/26/2013. Mary-Ann Fitzcharles is a consultant, speaker, or member of an advisory board for the following companies: Lilly, Purdue, Pfizer, Valeant
Mary-Ann Fitzcharles, MBChB Associate Professor of Medicine Division of Rheumatology and Alan and Louise Edwards Pain Management Center McGill University, Montreal Canada Mary-Ann Fitzcharles is a consultant,
More informationMANAGEMENT OF DIABETIC NEUROPATHY. Chungnam University Hospital Soo-Kyung, Bok, M.D., Ph.D.
MANAGEMENT OF DIABETIC NEUROPATHY Chungnam University Hospital Soo-Kyung, Bok, M.D., Ph.D. The Diabetic neuropathy cannot be reversed Not to restore function to damaged nerve Slowly progress no initial
More informationSUMMARY OF ARIZONA OPIOID PRESCRIBING GUIDELINES FOR THE TREATMENT OF CHRONIC NON-TERMINAL PAIN (CNTP)
9 SUMMARY OF ARIZONA OPIOID PRESCRIBING GUIDELINES FOR THE TREATMENT OF CHRONIC NON-TERMINAL PAIN (CNTP) SUMMARY OF ARIZONA OPIOID PRESCRIBING GUIDELINES FOR THE TREATMENT OF ACUTE PAIN NONOPIOID TREATMENTS
More informationFIBROMIALGIA: CLASSIFICAZIONE ED EPIDEMIOLOGIA DELLA SINDROME
FIBROMIALGIA: CLASSIFICAZIONE ED EPIDEMIOLOGIA DELLA SINDROME D.A. Filippini S.C. Reumatologia ASST Grande Ospedale Metropolitano Niguarda Milano MALATTIA DOLORE E RETE TERRITORIALE OSPEDALE NIGUARDA MILANO
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Neuropathic pain pharmacological management: the pharmacological management of neuropathic pain in adults in non-specialist
More informationTreatment of Neuropathic Pain: What Does the Evidence Say? or Just the Facts Ma am
Treatment of Neuropathic Pain: What Does the Evidence Say? or Just the Facts Ma am Tim R Brown, PharmD, BCACP, FASHP Director of Clinical Pharmacotherapy Cleveland Clinic Akron General Center for Family
More informationNurse Practitioners Education, Awareness, and Therapeutic Approaches for the Management of Fibromyalgia
RESEARCH 2.0 ANCC Contact Hours Nurse Practitioners Education, Awareness, and Therapeutic Approaches for the Management of Fibromyalgia Linda Hughes Jean Adair Feng Feng Stephanie Maciejewski Harsha Sharma
More informationRecommendations for the Management of Fibromyalgia
2011 UBM Medica. Reprinted with permission from Medical Progress 2011 Vol. 38 No. 1. Pain management Recommendations for the Management of Fibromyalgia The Multidisciplinary Panel on Neuropathic Pain Chen
More informationThis continuing education activity is co-sponsored by Indiana University School of Medicine and by CME Outfitters, LLC.
This continuing education activity is co-sponsored by Indiana University School of Medicine and by CME Outfitters, LLC. Indiana University School of Medicine and CME Outfitters, LLC, gratefully acknowledge
More informationIs Sodium Oxybate a Safe and Effective Treatment for Patients with Fibromyalgia
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2012 Is Sodium Oxybate a Safe and Effective
More informationFibromyalgia: Current Trends and Concepts
Fibromyalgia: Current Trends and Concepts Dr. Brian Kahan Fellow American Academy of Physical Medicine and Rehabilitation Diplomat American Academy of Pain Medicine American College of Rheumatology (ACR)
More informationPharmacological and Nonpharmacological Approaches
Pharmacological and Nonpharmacological Approaches NAS Workshop December 4, 2018 Kurt Kroenke, MD, MACP Indiana University School of Medicine Regenstrief Institute, Inc. Balanced Treatment Options Medications
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2018 P 3019-9 Program Step Therapy Medication Lyrica capsules, Lyrica Solution, Lyrica CR tablets* (pregabalin) P&T Approval Date 1/08,
More informationEvolving Treatments for Patients with Fibromyalgia
4:30pm - 5:30pm: Breakout 5 - Women s Health Option C: Evolving Treatments for Patients with Fibromyalgia ACPE UAN 0107-0000-10-027-L01-P 0.1 CEU/1.0 Hr. Activity Type: Application-Based Program Objectives
More informationCharacteristics and healthcare costs of patients with fibromyalgia syndrome
ORIGINAL PAPER Characteristics and healthcare costs of patients with fibromyalgia syndrome A. Berger, 1 E. Dukes, 2 S. Martin, 2 J. Edelsberg, 1 G. Oster 1 doi: 10.1111/j.1742-1241.2007.01480.x OnlineOpen:
More informationTreating Pain Based on the Underlying Mechanisms: Maybe sometimes it is all in their head...
Treating Pain Based on the Underlying Mechanisms: Maybe sometimes it is all in their head... Daniel J. Clauw M.D. dclauw@umich.edu Professor of Anesthesiology, Medicine (Rheumatology), and Psychiatry Director,
More informationMaking sense of fibromyalgia syndrome. Charles Radis D.O. Clinical Professor of Medicine UNECOM
Making sense of fibromyalgia syndrome Charles Radis D.O. Clinical Professor of Medicine UNECOM Goals 1. How do we diagnose fibromyalgia syndrome in patients presenting with widespread pain? 2. Discuss
More informationCHRONIC PAIN MANAGEMENT
CHRONIC PAIN MANAGEMENT Betty J Harris, PharmD. 2014 Objectives Explain the consequences of untreated pain. Identify common causes of chronic non-malignant pain in adults. Identify steps to assessing pain,
More informationChapter 23 Pharmacological therapies in fibromyalgia (chronic widespread pain)
Breivik_23.qxd 18/09/2006 11:34 Page 239 Chapter 23 Pharmacological therapies in fibromyalgia (chronic widespread pain) Srinivas G. Rao and Robert M. Bennett INTRODUCTION As detailed elsewhere in this
More informationIndex. Note: Page numbers of article titles are in boldface type. A ADHD. See Attention-deficit/hyperactivity disorder (ADHD) b-adrenergic blockers
Note: Page numbers of article titles are in boldface type. A ADHD. See Attention-deficit/hyperactivity disorder (ADHD) a-adrenergic blockers for PTSD, 798 b-adrenergic blockers for PTSD, 798 Adrenergic
More informationNeuropathic Pain in Palliative Care
Neuropathic Pain in Palliative Care Neuropathic Pain in Advanced Cancer Affects 40% of patients Multiple concurrent pains are common Often complex pathophysiology with mixed components Nocioceptive Neuropathic
More informationFibromyalgia: are you a believer?
Fibromyalgia: are you a believer? Shorin Nemeth, DO, FACOI Medical Director Comprehensive Pain Services Medical Director Oncology Palliative Care Providence Health and Services Portland, OR Disclosures
More informationLearning Objectives. Perioperative goals. Acute Pain in the Chronic Pain Patient for Ambulatory Surgery 9/8/16
Acute Pain in the Chronic Pain Patient for Ambulatory Surgery Danielle Ludwin, MD Associate Professor of Anesthesiology Division of Regional and Orthopedic Anesthesia Columbia University Medical Center
More informationMonte H. Moore, MD. Idaho Physical Medicine and Rehabilitation. Meridian, ID
Monte H. Moore, MD Idaho Physical Medicine and Rehabilitation Meridian, ID Chronic pain brief review Opiates important things to know Factors in determining whether to use an opiate What to watch for if
More informationCHAPTER 4 PAIN AND ITS MANAGEMENT
CHAPTER 4 PAIN AND ITS MANAGEMENT Pain Definition: An unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage. Types of Pain
More informationAssistant Professor. Dr.Khudair Al-bedri Consultant Rheumatology & Internal Medicine.
Assistant Professor Dr.Khudair Al-bedri Consultant Rheumatology & Internal Medicine. Fibromyalgia Fibromyalgia is a syndrome of chronic pain and the presence of hyperalgesic points at specific anatomical
More informationComparative Efficacy of Pharmacological and Nonpharmacological Interventions in Managing Primary and Secondary Outcomes of Fibromyalgia Syndrome
Literature Review Comparative Efficacy of Pharmacological and Nonpharmacological Interventions in Managing Primary and Secondary Outcomes of Fibromyalgia Syndrome * Medical University of the Americas,
More informationAvailable Strengths Limits. 10 mg tablet -- $ mg tablet -- $ mg tablet -- $ mg tablet -- $72.41 Avoid use in members over
MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Fibromyalgia P&T DATE: 5/9/2017 CLASS: Pain Management REVIEW HISTORY 9/15, 5/14, 11/12, 9/12, LOB: Medi-Cal (MONTH/YEAR)
More informationScottish Medicines Consortium
Scottish Medicines Consortium pregabalin, 25mg, 50mg, 75mg, 100mg, 150mg, 200mg, 225mg, 300mg capsules (Lyrica ) No. (389/07) Pfizer Limited 6 July 2007 The Scottish Medicines Consortium has completed
More informationNortriptyline vs amitriptyline in elderly
Nortriptyline vs amitriptyline in elderly Amitriptyline (Elavil ) vs other antidepressants - comparative analysis amitriptyline vs divalproate, amitriptyline vs trazodone. Learn what other patients are
More informationFibromyalgia in Family Medicine: Challenges in Pain Management
Fibromyalgia in Family Medicine: Challenges in Pain Management Evidence-based Recommendations The practice recommendations in this presentation are from: The European League Against Rheumatism (EULAR)
More informationFIBROMYALGIA INGRAM F ANDERSON. Consultant Rheumatologist
FIBROMYALGIA INGRAM F ANDERSON Consultant Rheumatologist Fibromyalgia is a riddle wrapped in a mystery inside an enigma Fibromyalgia not a new Disease. 1904: Gowers coined the term fibrositis to describe
More informationCannabinoids and Mental Health
Cannabinoids and Mental Health https://upload.wikimedia.org/wikipedia/commons Karen M. Lounsbury, PhD Professor of Pharmacology 802-656-3231, Karen.lounsbury@uvm.edu Objectives Describe the underlying
More informationOh My Aching Body Understanding Fibromyalgia
Page 1 Oh, My Aching Body: Understanding Fibromyalgia Geneva Clark Briggs, PharmD, BCPS This program has been brought to you by PharmCon Oh, My Aching Body: Understanding Fibromyalgia Accreditation: Pharmacists:
More informationAntipsychotic Medications
TRAIL: Team Review of EVIDENCE REVIEW & RECOMMENDATIONS FOR LTC Behavioural and psychological symptoms of dementia (BPSD) refer to the non-cognitive symptoms of disturbed perception, thought content, mood
More informationAchieving Optimal Therapeutic Outcomes in Pain Management from a Pharmacist's Perspective
Achieving Optimal Therapeutic Outcomes in Pain Management from a Pharmacist s Perspective Chris Herndon, PharmD, BCPS, CPE Assistant Professor Southern Illinois University Edwardsville Clinical Pharmacy
More informationSpinal Cord Injury Pain. Michael Massey, DO CentraCare Health St Cloud, MN 11/07/2018
Spinal Cord Injury Pain Michael Massey, DO CentraCare Health St Cloud, MN 11/07/2018 Objectives At the conclusion of this session, participants should be able to: 1. Understand the difference between nociceptive
More informationPain CONCERN. Medicines for long-term pain. Antidepressants
Pain CONCERN Medicines for long-term pain Antidepressants Many people living with long-term pain (also known as chronic or persistent pain) are worried about using medicines like antidepressants. They
More informationObjectives. Objectives. Fibromyalgia overview 2/13/2013. Disclosure. FM research has flourished since 1980s. Acceptance fibromyalgia as a diagnosis
Fibromyalgia overview Robert Bennett M.D. Professor of Medicine Mdii and Nursing OHSU Disclosure Research support : Forest, Jazz, Pfizer Advisory Boards: Lilly, Jazz Speaker Bureaus: None Objectives Objectives
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Lyrica) Reference Number: HIM.PA.64 Effective Date: 12/14 Last Review Date: 08/17 Line of Business: Health Insurance Marketplace Revision Log See Important Reminder at the end of this
More informationMultiple Mechanisms for Pain - How Can We Improve the Chances of Success?
Multiple Mechanisms for Pain - How Can We Improve the Chances of Success? Ann Hayes October 2017 What are the different types of pain? Neuropathic Diabetic neuropathy, PHN, sciatica Caused by damage to
More informationFIBROMYALGIA. Howard L. Feinberg, D.O. F.A.C.O.I., F.A.C.R. OPSC San Diego 2017
FIBROMYALGIA Howard L. Feinberg, D.O. F.A.C.O.I., F.A.C.R. OPSC San Diego 2017 Sir William Osler When a patient with arthritis comes in the front door, I try to go out the back door. FEINBERG S COROLLARY
More informationCymbalta anti inflammatory
Cymbalta anti inflammatory The Borg System is 100 % Cymbalta anti inflammatory 11/01/2017 Abcya math man games 11/02/2017 Lalaloopsy 11/03/2017 Free keno wheels Cymbalta and ibuprofen. View detailed information
More informationCOMPOUNDING PHARMACY SOLUTIONS PRESCRIPTION COMPOUNDING FOR PAIN MANAGEMENT
JANUARY 2012 COMPOUNDING PHARMACY SOLUTIONS PRESCRIPTION COMPOUNDING WWW.CPSRXS. COM We customize individual prescriptions for the specific needs of our patients. INSIDE THIS ISSUE: Osteoarthritis Pain
More informationSpine University s Guide to Fibromyalgia
Spine University s Guide to Fibromyalgia 2 Introduction The official name for fibromyalgia is fibromyalgia syndrome. Fibro means fiber and myalgia means muscular pain or tenderness. Fibromyalgia has been
More informationReview. Pharmacological treatment of fibromyalgia
Review Pharmacological treatment of fibromyalgia M. Di Franco 1, C. Iannuccelli 1, F. Atzeni 2, M. Cazzola 3, F. Salaffi 4, G. Valesini¹, P. Sarzi-Puttini 2 1 Chair of Rheumatology, Sapienza, University
More informationAnxiolytic, Sedative and Hypnotic Drugs. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia
Anxiolytic, Sedative and Hypnotic Drugs Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Anxiolytics: reduce anxiety Sedatives: decrease activity, calming
More informationFibromyalgia is derived from Greek
FIBROMYALGIA: A OMPLEX PAIN PROBLEM ABSTRAT Fahim Anwar 1, S. Fahim 2 Fibromyalgia is derived from Greek words, fibro meaning fibrous tissue, myo meaning muscle and algos meaning pain. It is characterized
More informationTherapeutic Advances in Musculoskeletal Disease
483894TAB5310.1177/1759720X13483894Therapeutic Advances in Musculoskeletal DiseasePJ Mease, MV Farmer 2013 Therapeutic Advances in Musculoskeletal Disease Original Research Milnacipran combined with pregabalin
More informationCNS Depressants and Anti-Inflammatory Medications Used in Fibromyalgia Disease
INTERNATIONAL JOURNAL OF ADVANCES IN PHARMACY, BIOLOGY AND CHEMISTRY Review Article CNS Depressants and Anti-Inflammatory Medications Used in Fibromyalgia Disease Usha Verma*, Sanjita Das and Saumya Das
More informationGuilt Suicidality. Depression Co-Occurs with Medical Illness The rate of major depression among those with medical illness is significant.
1-800-PSYCH If you are obsessive-compulsive, dial 1 repeatedly If you are paranoid-delusional, dial 2 and wait, your call is being traced If you are schizophrenic, a little voice will tell you what number
More informationTITLE: Gabapentin for HIV-associated Neuropathic Pain: A Review of the Clinical Effectiveness
TITLE: Gabapentin for HIV-associated Neuropathic Pain: A Review of the Clinical Effectiveness DATE: 22 January 2016 CONTEXT AND POLICY ISSUES Neuropathic pain can be severe and debilitating and results
More informationEARN 3 FREE CPD POINTS
Leader in digital CPD for Southern African healthcare professionals EARN 3 FREE CPD POINTS Neuroscience Pregabalin A wideranging medication Introduction Pregabalin was used initially as an anxiolytic in
More informationOn March 21, 2009, The American Journal of Managed Care
n report n Contemporary Management Strategies for Fibromyalgia On March 21, 2009, The American Journal of Managed Care (AJMC) held a roundtable of clinical, patient advocacy, and managed care experts to
More informationFIBROMYALGIA. Leena Mathew, M.D. Director Pain Fellowship Associate Professor Department of Anesthesiology Columbia University
FIBROMYALGIA Leena Mathew, M.D. Director Pain Fellowship Associate Professor Department of Anesthesiology Columbia University disclosures I have no conflicts of interest objectives Be able to accurately
More informationElements for a Public Summary
VI.2 Elements for a Public Summary VI.2.1 Overview of disease epidemiology Generalised anxiety disorder Generalised anxiety disorder (GAD) is an umbrella term that covers a wide range of anxiety disorders
More informationAddressing Fibromyalgia: From Timely Diagnosis to Individualizing Treatment
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationPain Management and Safe use of opioids in hospitals. Kyoung-Sil Kang, PharmD, BCPS Scott Tam, PharmD Lauve Casimir, RN, MSN
Pain Management and Safe use of opioids in hospitals Kyoung-Sil Kang, PharmD, BCPS Scott Tam, PharmD Lauve Casimir, RN, MSN Bronx Care Health System Bronx Lebanon Hospital Concourse/ Fulton division, Nursing
More informationAdvice following an Independent Review Panel (IRP)
Scottish Medicines Consortium Advice following an Independent Review Panel (IRP) Pregabalin 25, 50, 75, 100, 150, 200 and 300mg capsules (Lyrica ) Pfizer No. 157/05 7 July 2006 The Scottish Medicines Consortium
More information9/6/2011. Objectives THE FIBROMYALGIA SYNDROME: HOW FAR HAVE WE COME IN OUR UNDERSTANDING & MANAGEMENT
THE FIBROMYALGIA SYNDROME: HOW FAR HAVE WE COME IN OUR UNDERSTANDING & MANAGEMENT Theresa Mallick-Searle Nurse Practitioner Stanford University Medical Center: Division Pain Management tmallick@stanfordmed.org
More informationAuthor: Gibler/Ketchum Date: March 2015
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationCHAPTER 4 PAIN AND ITS MANAGEMENT
CHAPTER 4 PAIN AND ITS MANAGEMENT Pain Definition: An unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage. Types of Pain
More informationFibromyalgia. Resident School December 2013 Mary Lemon
Fibromyalgia Resident School December 2013 Mary Lemon The Basics Condition that causes people to feel pain in the muscles all over their body No one knows what causes it; appears to be a combo of genetic
More informationTreating Pain and Depression
Treating Pain and Depression Without Getting Depressed Joseph P, Arpaia, MD www.jparpaiamd.com More than 50% of patients with chronic pain also have clinically significant depression. Interestingly that
More informationTreating sleep disorders
Treating sleep disorders Sue Wilson Centre for Neuropsychopharmacology Imperial College London sue.wilson@imperial.ac.uk Suggested algorithm for treatment of insomnia Diagnosis of insomnia Associated with
More informationZonisamide for migraine prophylaxis in refractory patients
Thomas Jefferson University Jefferson Digital Commons Department of Neurology Faculty Papers Department of Neurology March 2006 Zonisamide for migraine prophylaxis in refractory patients Avi Ashkenazi
More informationOptimal Use of Antidepressants: Focusing on SNRI, NDRI and SSRE
Optimal Use of Antidepressants: Focusing on SNRI, NDRI and SSRE Chan-Hyung Kim, MD Severance Mental Health Hospital Institute of Behavioral Science in Medicine Diagnostic Criteria Pyramid Etiologic Pathophysiologic
More informationDisclosures. Objectives 9/8/2015
The Aftermath of the Decade of Pain: Alternatives to Opioids in Chronic Pain Management Julie Cunningham, PharmD, BCPP Disclosures No relevant financial disclosures I will discuss off-label uses of antiepileptics,
More informationPain and fibromyalgia
Jatin D Dedhia DA DNB FRCA Margaret E Bone DA FRCA FFPMRCA Key points Fibromyalgia is a common chronic pain syndrome characterized by widespread pain, tenderness, and generalized hypersensitivity to painful
More informationPennsylvania Academy of Family Physicians Foundation & UPMC 43rd Refresher Course in Family Medicine CME Conference March 10-13, 2016
Pennsylvania Academy of Family Physicians Foundation & UPMC 43rd Refresher Course in Family Medicine CME Conference March 10-13, 2016 Disclosures: Fibromyalgia Update Wayne Blount, MD Speaker has no disclosures
More informationProceedings of the 36th World Small Animal Veterinary Congress WSAVA
www.ivis.org Proceedings of the 36th World Small Animal Veterinary Congress WSAVA Oct. 14-17, 2011 Jeju, Korea Next Congress: Reprinted in IVIS with the permission of WSAVA http://www.ivis.org 14(Fri)
More informationPharmacological treatment of Pain
Pharmacological treatment of Pain None Disclosures and Conflict of Interest Dr John F. Flannery Medical Director MSK and Multisystem Rehab Program PMR - FRCPC Objectives At the end of this presentation
More informationRational Polypharmacy
Rational Polypharmacy Thomas B. Gregory, PharmD, BCPS, CPE, FASPE Disclosures Clinical advisory board: Daiichi Sankyo 1 Introduction Cox Health Ambulatory Pain Clinic Pharmacy Specialist Learning Objectives
More informationOut with the Old In with the New: Novel, Neuroscience-Based Re-Classification of Psychiatric Medications
Program Outline Out with the Old In with the New: Novel, Neuroscience-Based Re-Classification of Psychiatric Medications Rajiv Tandon, MD Professor of Psychiatry University of Florida College of Medicine
More informationFibromyalgia Fact and Fiction
Fibromyalgia Fact and Fiction Paul Howard, MD FACP FACR 9097 E. Desert Cove Ave Suite 100 Scottsdale, Arizona 85260 480-609-4200 fax: 480-609-4233 paul.howard@arthritishealth.net Disclosure of Financial
More informationVI.2 Elements for a Public Summary DULOXETINE Pharmalex 30 mg hard gastro-resistant capsules DULOXETINE Pharmalex 60 mg hard gastro-resistant capsules
VI.2 Elements for a Public Summary DULOXETINE Pharmalex 30 mg hard gastro-resistant capsules DULOXETINE Pharmalex 60 mg hard gastro-resistant capsules VI.2.1 Overview of disease epidemiology Depression
More informationPeripheral Subcutaneous Field Stimulation. Description
Subject: Peripheral Subcutaneous Field Stimulation Page: 1 of 6 Last Review Status/Date: June 2016 Peripheral Subcutaneous Field Stimulation Description Peripheral subcutaneous field stimulation (PSFS,
More informationDRUGS THAT ACT IN THE CNS
DRUGS THAT ACT IN THE CNS Anxiolytic and Hypnotic Drugs Dr Karamallah S. Mahmood PhD Clinical Pharmacology 1 OTHER ANXIOLYTIC AGENTS/ A. Antidepressants Many antidepressants are effective in the treatment
More informationFibromyalgia. What is fibromyalgia? What causes fibromyalgia? Who gets fibromyalgia? What are the symptoms of fibromyalgia?
Page 1 of 5 Fibromyalgia Fibromyalgia typically causes persistent pains and tenderness in many areas of the body as well as tiredness. You may also have other symptoms. There is no simple 'once and for
More informationPsychopharmacology. Psychopharmacology. Hamish McAllister-Williams Reader in Clinical. Department of Psychiatry, RVI
Regional Affective Disorders Service Psychopharmacology Northumberland, Tyne and Wear NHS Trust Hamish McAllister-Williams Reader in Clinical Psychopharmacology Department of Psychiatry, RVI Intro NOT
More informationThe Impact of Centralized Pain on Acute and Chronic Post-surgical Pain
The Impact of Centralized Pain on Acute and Chronic Post-surgical Pain Chad M. Brummett, M.D. Associate Professor Director, Clinical Anesthesia Research Director, Pain Research Department of Anesthesiology
More informationpdpn early screening and management
pdpn early screening and management The Hidden Faces of Diabetes Summit was held in Johannesburg, South Africa, from 20 to 21 September 2014. Organized by Pfizer Middle East and Africa, the interactive
More informationIs Major Depression More Commonly associated with Widespread Pain? A Cross-sectional Study to identify Any Relation
ORIGINAL ARTICLE Is Major Depression More Commonly 10.5005/jp-journals-10046-0097 associated with Widespread Pain Is Major Depression More Commonly associated with Widespread Pain? A Cross-sectional Study
More informationPotential drug therapies for the treatment of fibromyalgia
Potential drug therapies for the treatment of fibromyalgia LAWSON, Kim Available from Sheffield Hallam University Research Archive (SHURA) at: http://shura.shu.ac.uk/12861/
More informationNon-opioid and adjuvant pain management
Non-opioid and adjuvant pain management ALLISON JORDAN, MD, HMDC MEDICAL DIRECTOR OF PALLIATIVE CARE SERVICES CHRISTIAN AND ALTON MEMORIAL HOSPITALS ASSOCIATE MEDICAL DIRECTOR, BJC HOSPICE ASSISTANT PROFESSOR
More informationRefractory Central Neurogenic Pain in Spinal Cord Injury. Case Presentation
Refractory Central Neurogenic Pain in Spinal Cord Injury Case Presentation Edwin B. George, MD, PhD Wayne State University John D. Dingell VAMC 2012 Disclosures This continuing education activity is managed
More informationPRESCRIBING PRACTICE IN DELIRIUM. John Warburton Critical Care Pharmacist
PRESCRIBING PRACTICE IN DELIRIUM John Warburton Critical Care Pharmacist Learning outcomes Modifiable medication risk factors for delirium An appreciation of contributing factors modifiable with medicines
More informationNEUROPATHIC CANCER PAIN STANDARDS AND GUIDELINES
NEUROPATHIC CANCER PAIN STANDARDS AND GUIDELINES GENERAL PRINCIPLES Neuropathic pain may be relieved in the majority of patients by multimodal management A careful history and examination are essential.
More informationsodium oxybate, 500mg/ml oral solution (Xyrem) No. (246/06) UCB Pharma Ltd
Scottish Medicines Consortium Resubmission sodium oxybate, 500mg/ml oral solution (Xyrem) No. (246/06) UCB Pharma Ltd 10 August 2007 The Scottish Medicines Consortium has completed its assessment of the
More information